More than 1 in 8 American adults are using GLP-1’s for weight loss. Experts say these are the nutritional gaps and side effects that should not to be overlooked.

Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric ...

In an emotional video, actress and comedian Mo'Nique urged her fans to consider the dangers of using a GLP-1 for weight loss.

Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

Behind the buzz around Mounjaro lies a larger conversation about who really needs it.

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...